Syndax Pharmaceuticals Inc. (Nasdaq: SNDX) announced that patients in the ENCORE 601 non-small cell lung cancer trial will advance to the second stage of the Phase 2 trial. Shares of the biopharmaceutical leaped $4.19 to close at $13.58.
Syndax Pharmaceuticals trial advances to stage 2
May 17, 2017 at 17:35 PM EDT
